BR112019022321A2 - Tcr e peptídeos - Google Patents

Tcr e peptídeos Download PDF

Info

Publication number
BR112019022321A2
BR112019022321A2 BR112019022321-5A BR112019022321A BR112019022321A2 BR 112019022321 A2 BR112019022321 A2 BR 112019022321A2 BR 112019022321 A BR112019022321 A BR 112019022321A BR 112019022321 A2 BR112019022321 A2 BR 112019022321A2
Authority
BR
Brazil
Prior art keywords
tcr
peptides
mhc
binds
peptide
Prior art date
Application number
BR112019022321-5A
Other languages
English (en)
Inventor
Chiara Bonini Maria
Ruggiero Eliana
Irene Magnani Zulma
Aldo Edoardo Vago Luca
Bondanza Attilio
Ciceri Fabio
Original Assignee
Ospedale San Raffaele S.R.L.
Fondazione Centro San Raffaele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele S.R.L., Fondazione Centro San Raffaele filed Critical Ospedale San Raffaele S.R.L.
Publication of BR112019022321A2 publication Critical patent/BR112019022321A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a um receptor de células t (tcr) que se liga a um peptídeo da proteína 1 de tumor de wilms (wt1) quando apresentado por um complexo principal de histocompatibilidade (mhc).
BR112019022321-5A 2017-04-24 2018-04-24 Tcr e peptídeos BR112019022321A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489226P 2017-04-24 2017-04-24
US62/489,226 2017-04-24
PCT/EP2018/060477 WO2018197492A1 (en) 2017-04-24 2018-04-24 Tcr and peptides

Publications (1)

Publication Number Publication Date
BR112019022321A2 true BR112019022321A2 (pt) 2020-05-26

Family

ID=62116393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022321-5A BR112019022321A2 (pt) 2017-04-24 2018-04-24 Tcr e peptídeos

Country Status (15)

Country Link
US (2) US11597755B2 (pt)
EP (1) EP3615565A1 (pt)
JP (2) JP7328211B2 (pt)
KR (1) KR20200020681A (pt)
CN (1) CN110785432A (pt)
AU (2) AU2018259029B2 (pt)
BR (1) BR112019022321A2 (pt)
CA (1) CA3060343A1 (pt)
EA (1) EA201992536A1 (pt)
MX (1) MX2023012065A (pt)
PH (1) PH12019502400A1 (pt)
SA (1) SA519410362B1 (pt)
SG (1) SG11201909864TA (pt)
TW (1) TWI835730B (pt)
WO (1) WO2018197492A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201803178D0 (en) * 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CN109679917B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft2细胞
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
JP2022525099A (ja) * 2019-03-11 2022-05-11 フレッド ハッチンソン キャンサー リサーチ センター 高アビディティｗｔ１ｔ細胞受容体とその使用
EP3941491A4 (en) 2019-03-21 2023-03-29 Gigamune, Inc. ENGINEERED CELLS EXPRESSING ANTIVIRAL T-CELL RECEPTORS AND METHODS OF USE
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CN112279908B (zh) * 2020-10-23 2024-03-19 魏放 识别ebv抗原短肽的t细胞受体及其应用
CN112521484A (zh) * 2020-12-03 2021-03-19 佛山市第一人民医院（中山大学附属佛山医院） 结肠癌肿瘤特异tcr序列及其应用
JP2024512808A (ja) * 2021-04-05 2024-03-19 ヤンセン バイオテツク，インコーポレーテツド Ｃａｌｒ及びｊａｋ２ｔ細胞受容体
WO2023081655A1 (en) * 2021-11-02 2023-05-11 Fred Hutchinson Cancer Center T cell immunotherapy for hematologic malignancies having an sf3b1 mutation
WO2023091420A2 (en) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions and methods for t cell engineering
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023193800A1 (zh) * 2022-04-07 2023-10-12 恺兴生命科技(上海)有限公司 嵌合多肽及其应用
WO2024081915A1 (en) * 2022-10-13 2024-04-18 Ann And Robert H. Lurie Children's Hospital Of Chicago Capture agents for detection of kawasaki disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
JP6433894B2 (ja) * 2012-07-27 2018-12-05 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Ｔ細胞受容体の操作
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
TR201908404T4 (tr) * 2013-11-22 2019-07-22 Hutchinson Fred Cancer Res İşlenmiş yüksek afinite insan t hücresi reseptörleri.
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
EP3277294B1 (en) * 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target

Also Published As

Publication number Publication date
WO2018197492A1 (en) 2018-11-01
EA201992536A1 (ru) 2020-03-05
SG11201909864TA (en) 2019-11-28
CN110785432A (zh) 2020-02-11
US20200123220A1 (en) 2020-04-23
JP2020517308A (ja) 2020-06-18
AU2018259029A1 (en) 2019-12-12
SA519410362B1 (ar) 2024-01-18
AU2024203874A1 (en) 2024-08-29
US20240132569A1 (en) 2024-04-25
JP7328211B2 (ja) 2023-08-16
AU2018259029B2 (en) 2024-03-07
PH12019502400A1 (en) 2021-01-25
KR20200020681A (ko) 2020-02-26
MX2023012065A (es) 2023-10-23
US11597755B2 (en) 2023-03-07
CA3060343A1 (en) 2018-11-01
TWI835730B (zh) 2024-03-21
EP3615565A1 (en) 2020-03-04
JP2023145687A (ja) 2023-10-11
TW201900675A (zh) 2019-01-01

Similar Documents

Publication Publication Date Title
BR112019022321A2 (pt) Tcr e peptídeos
BR112017023409A2 (pt) ?célula t que expressa um receptor de célula t gama-delta (tcr) e um receptor de antígeno quimérico (car)
PH12017502190A1 (en) T-cell receptor specific antibodies
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
MX2018012897A (es) Nuevos polipeptidos biespecificos contra cd137.
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
BR112016021004A2 (pt) biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
CO2020009644A2 (es) Esteroides y conjugados de anticuerpos de los mismos
BR112016012358A2 (pt) peptídios terapêuticos
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t
BR112018002386A8 (pt) Anticorpo contra glypican-3 e aplicação do mesmo
PH12017501863A1 (en) Bioconjugates and uses thereof
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
BR112016022727A2 (pt) ?imunorreceptores específicos de claudina-6 e epítopos de células t
BR112018001683A2 (pt) adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
WO2020089433A3 (en) Tcr and peptides
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112019008345A2 (pt) anticorpos monoclonais ligados à isoforma transmembrana cd160
BR112016001782A2 (pt) Proteína de fusão terapêutica
BR112018073136A2 (pt) métodos para tratar doença autoimune usando células t alogênicas
BR112021016198A2 (pt) Formulações de anticorpo anti-il-36r

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]